Molgramostim nebulizer solution
Phase 2Terminated 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mycobacterium Infections, Nontuberculous
Conditions
Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF)
Trial Timeline
Jun 20, 2019 → Oct 2, 2020
NCT ID
NCT03597347About Molgramostim nebulizer solution
Molgramostim nebulizer solution is a phase 2 stage product being developed by Savara for Mycobacterium Infections, Nontuberculous. The current trial status is terminated. This product is registered under clinical trial identifier NCT03597347. Target conditions include Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF).
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06546098 | Pre-clinical | Active |
| NCT03597347 | Phase 2 | Terminated |
Competing Products
20 competing products in Mycobacterium Infections, Nontuberculous